Head-To-Head Comparison: Becton, Dickinson and Company (NYSE:BDX) & Calmare Therapeutics (OTCMKTS:CTTC)

Calmare Therapeutics (OTCMKTS:CTTC) and Becton, Dickinson and Company (NYSE:BDX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Valuation and Earnings

This table compares Calmare Therapeutics and Becton, Dickinson and Company”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calmare Therapeutics	N/A	N/A	N/A	N/A	N/A
Becton, Dickinson and Company	$20.64 billion	3.18	$1.71 billion	$6.02	37.98

Becton, Dickinson and Company has higher revenue and earnings than Calmare Therapeutics.

Insider & Institutional Ownership

87.0% of Becton, Dickinson and Company shares are held by institutional investors. 17.5% of Calmare Therapeutics shares are held by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Calmare Therapeutics and Becton, Dickinson and Company’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calmare Therapeutics	N/A	N/A	N/A
Becton, Dickinson and Company	8.47%	15.74%	7.29%

Analyst Recommendations

This is a breakdown of current recommendations for Calmare Therapeutics and Becton, Dickinson and Company, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calmare Therapeutics	0	0	0	0	0.00
Becton, Dickinson and Company	0	0	7	0	3.00

Becton, Dickinson and Company has a consensus price target of $278.29, suggesting a potential upside of 21.71%. Given Becton, Dickinson and Company’s stronger consensus rating and higher possible upside, analysts plainly believe Becton, Dickinson and Company is more favorable than Calmare Therapeutics.

Summary

Becton, Dickinson and Company beats Calmare Therapeutics on 8 of the 9 factors compared between the two stocks.

About Calmare Therapeutics

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.